徐州多少个月做四维彩超徐州四维正规的医院,徐州四维彩超的意义,徐州做四维哪家医院不用预约,徐州胃透和肠镜那个好,徐州怀孕两个月的孕酮值,徐州明天做四维要注意什么,徐州做肠镜 的费用

WASHINGTON, Nov. 10 (Xinhua) -- NASA's car-sized Mars rover Curiosity, which will examine one of the most intriguing areas on the Red Planet, is in final preparations for a launch from Florida 's Space Coast at 10:25 a.m. EST (15:25 GMT) on Nov. 25, the U.S. space agency announced on Thursday.Curiosity is about twice as long and more than five times as heavy as any previous Mars rover. Its 10 science instruments include two for ingesting and analyzing samples of powdered rock delivered by the rover's robotic arm. It is now sitting atop an Atlas V rocket awaiting liftoff from Cape Canaveral Air Force Station."Preparations are on track for launching at our first opportunity," said Pete Theisinger, Mars Science Laboratory project manager at NASA's Jet Propulsion Laboratory. "If weather or other factors prevent launching then, we have more opportunities through Dec. 18."Scheduled to land on the Mars in Aug. 2012, the one-ton rover will examine Gale Crater during a nearly two-year prime mission. Curiosity will land near the base of a layered mountain three miles (five kilometers) high inside the crater. The rover will investigate whether environmental conditions ever have been favorable for development of microbial life and preserved evidence of those conditions.

BERLIN, Jan. 17 (Xinhua) -- Researchers in Germany have found a cheap and easy way to synthesize anti-malaria drug in large quantities from waste materials, said the Max Planck Society on Tuesday.Currently there are nearly one million people die worldwide each year due to lack of effective drugs, as sweet wormwood, from which artemisinin, the effective essence to fight malaria can be extracted, only grows in China, Vietnam and a few other countries.However, researchers in Germany have now developed a simple process for the synthesis of artemisinin in laboratory, using artemisinic acid, a substance contained in the by-product, or waste materials of the isolation of artemisinin from sweet wormwoods, as row materials of synthesizing artemisinin."The production of the drug is therefore no longer dependent on obtaining the active ingredient from plants," said Peter Seeberger, director at the Max Planck Institute of Colloids and Interfaces in Potsdam and professor at Free University of Berlin.The artemisinic acid in the waste material boasts a volume 10 times greater than the active ingredient itself, said Seeberger, and they could be turned into artemisinin in four and a half minutes in a so-called continuous-flow reactor.Seeberger estimated that 800 of the reactors would be enough to cover the global requirement for artemisinin, and the whole innovative synthesis process could be ready for technical use in three to six months.Malaria is a disease caused by parasites that are transmitted to people through the bites of infected mosquitoes. In 2010, malaria caused an estimated 655,000 deaths, mostly among African children.

WASHINGTON, Dec. 28 (Xinhua) -- People with diets high in several vitamins or in omega 3 fatty acids are less likely to have the brain shrinkage associated with Alzheimer's disease than people whose diets are not high in those nutrients, according to a new study published on Wednesday in the online issue of Neurology, the medical journal of the American Academy of Neurology.Those with diets high in omega 3 fatty acids and in vitamins C, D, E and the B vitamins also had higher scores on mental thinking tests than people with diets low in those nutrients. These omega 3 fatty acids and vitamin D are primarily found in fish. The B vitamins and antioxidants C and E are primarily found in fruits and vegetables.In another finding, the study showed that people with diets high in trans fats were more likely to have brain shrinkage and lower scores on the thinking and memory tests than people with diets low in trans fats. Trans fats are primarily found in packaged, fast, fried and frozen food, baked goods and margarine spreads.The study involved 104 people with an average age of 87 and very few risk factors for memory and thinking problems. Blood tests were used to determine the levels of various nutrients present in the blood of each participant. All of the participants also took tests of their memory and thinking skills. A total of 42 of the participants had MRI scans to measure their brain volume. Overall, the participants had good nutritional status, but seven percent were deficient in vitamin B12 and 25 percent were deficient in vitamin D.Study author Gene Bowman, of Oregon Health & Science University in Portland, said that the nutrient biomarkers in the blood accounted for a significant amount of the variation in both brain volume and thinking and memory scores. For the thinking and memory scores, the nutrient biomarkers accounted for 17 percent of the variation in the scores. For brain volume, the nutrient biomarkers accounted for 37 percent of the variation."These results need to be confirmed, but obviously it is very exciting to think that people could potentially stop their brains from shrinking and keep them sharp by adjusting their diet," Bowman said.

BEIJING, Oct. 24 (Xinhuanet) -- The average global land temperature has increased by around one degree Cetigrade since the mid-1950s, American scientists announced last week after reviewing historical temperature records to date.According to media reports, the scientists of the Berkeley Earth project have studied more than a billion temperature records dating back to the 1800s from 15 sources around the world.And the result is in line with the estimate made by major institutions which keep official records on the global climate, including the Nasa's Goddard Institute for Space Studies in the US and the Met Office's Hadley Centre in Britain.Meanwhile, the scientists established an open database for the climate records so that skeptics on climate change can assess climage change on their own.Nevertheless, the finding of the scientists at the University of California, Berkeley did not convince climate change skeptics, according to a New York Times report.Anthony Watts, one prominent US skeptics, claimed the study's "methodology was flawed". He also noted that the finding was submitted to journal Geophysical Research Letters before being peer-reviewed.Richard Muller, a physicist and head of the project, argued that the decision to circulate the papers before publication was part a long-standing academic tradition of sanity-checking results with colleagues.He added, cited by the Guardian, "We will get much more feedback from making these papers public before publication."

WASHINGTON, Jan. 19 (Xinhua) -- New research published this week in Nature Medicine indicates that targeted drugs such as gefitinib might more effectively treat non-small cell lung cancer if they could be combined with agents that block certain microRNAs.The study, led by investigators with the Ohio State University Comprehensive Cancer Center, shows that overexpression of two genes called MET and EGFR causes the deregulation of six microRNAs, and that this deregulation leads to gefitinib resistance.The findings support the development of agents that restore the levels of these microRNAs. It offers a new strategy for treating non-small cell lung cancer, which is responsible for about 85 percent of the 221,000 lung-cancer cases and 157,000 deaths that occur annually in the United States. It also suggests that measuring the expression levels of certain microRNAs -- those controlled by the MET gene -- might predict which lung-cancer cases are likely to be resistant to gefitinib.Epidermal growth factor receptor (EGFR) is frequently overexpressed in non-small cell lung cancer, and this leads to uncontrolled cell proliferation. Gefitinib selectively inhibits EGFR activation and triggers cancer cells to self-destruct by apoptosis. However, non-small cell lung cancer cells inevitably develop resistance to the drug. The study reveals how this resistance occurs."Our findings suggest that gefitinib resistance that is caused by MET overexpression is at least partly due to miRNA deregulation, " says principal investigator Carlo Croce.